Alzheimer’s disease (AD) is the most common cause of dementia. Although AD was initially considered to be a cell autonomous neurodegenerative disorder, marked neuroinflammation has been observed in brains of AD patients. Genetic and molecular biological findings have suggested the central nervous system (CNS) inflammatory processes to be involved in the etiopathogenesis of AD, in which the activated microglia play a key role. This has also been supported by epidemiological observation that CNS infections are associated with the development of AD, and the relationship between herpes simplex virus (HSV)-1 and AD has been particularly well investigated [1]. For example, the presence of anti-HSV antibody is associated with an elevated risk of AD [2]. Anti-herpetic medication is associated with a reduced risk of dementia in a population-based study [1]. Similar results have also been observed in varicella zoster virus (VZV) infections [3]. In this study, we enrolled 9 patients with HSV infection of the CNS, 8 patients with herpes zoster complicated by CNS involvement, and 18 age-matched control patients presenting with neither CNS infection nor dementia, and measured cerebral spinal fluid (CSF) levels of Aβ in CSF of patients with HSV encephalitis [4, 5]. The CSF t-tau, p-tau, sTREM2, and GFAP levels were significantly elevated in the HSV + VZV combined group (HSV/VZV) compared with the control group (p = 0.01836, 0.0380, and 0.0262, respectively) (Fig. 1a–c). The CSF t-tau, p-tau, sTREM2, and GFAP levels were significantly elevated in the HSV/VZV group compared with the control group (p = 0.0043, 0.0007, 0.0030, and 0.0139, respectively) (Fig. 1d, e, i, and j). These results correspond to previous reports showing significantly decreased Aβ1–42, increased t-tau, and increased p-tau in CSF of patients with HSV encephalitis [4, 5]. The CSF p-tau/t-tau, CSF NfL, CSF p-NfH and serum NfL levels did not significantly differ between the HSV/VZV and control groups (Fig. 1f, g, h, and k). Comparison among the HSV, VZV and control groups showed that the elevation of CSF p-tau was significant in the VZV group while the level of CSF t-tau was elevated specifically in the HSV group (Supplementary Fig. S1). The other biomarkers showed similar trends to those in comparison between HSV/VZV and the control groups.

Results of uni- and multivariate regression analyses between those biomarker values and clinical severity are summarized in Supplementary Table S3. The negative correlations between Glasgow coma scale and NfL in biomarker for microglial activity; and glial fibrillary acidic protein (GFAP) as a biomarker for astrocytic damage. We also measured serum levels of NfL as a blood-based biomarker for axonal injury. Detailed methods are provided in Supplementary Methods. There was no significant difference in age or sex among the HSV, VZV, and control groups (Table S1). The raw data on biomarkers are presented in Table S2.

We found that the levels of CSF Aβ1–42, Aβ1–40, and the Aβ1–42/Aβ1–40 ratio were significantly lower in the HSV + VZV combined group (HSV/VZV) compared with the control group (p = 0.0003, 0.0007, and 0.0139, respectively) (Fig. 1a–c). The CSF t-tau, p-tau, sTREM2, and GFAP levels were significantly elevated in the HSV/VZV group compared with the control group (p = 0.0043, 0.0007, 0.0030, and 0.0139, respectively) (Fig. 1d, e, i, and j). These results correspond to previous reports showing significantly decreased Aβ1–42, increased t-tau, and increased p-tau in CSF of patients with HSV encephalitis [4, 5]. The CSF p-tau/t-tau, CSF NfL, CSF p-NfH and serum NfL levels did not significantly differ between the HSV/VZV and control groups (Fig. 1f, g, h, and k). Comparison among the HSV, VZV and control groups showed that the elevation of CSF p-tau was significant in the VZV group while the level of CSF t-tau was elevated specifically in the HSV group (Supplementary Fig. S1). The other biomarkers showed similar trends to those in comparison between HSV/VZV and the control groups.

Results of uni- and multivariate regression analyses between those biomarker values and clinical severity are summarized in Supplementary Table S3. The negative correlations between Glasgow coma scale and NfL in...
CSF and serum were significant after age adjustment ($p = 0.014$ and 0.030, respectively). Among the biomarkers, only CSF NfL was significantly correlated with the Modified Rankin Scale on discharge after age adjustment ($p = 0.018$). Supplementary Fig. S2 shows scatter plots in cases showing significant correlations on univariate analyses.

The current study has three major implications. First, to our best knowledge, this is the first report of CSF p-tau elevation in patients with CNS VZV infection. This suggests that the biomarker profile of decreased $A\beta_{1-42}$, and increased t-tau and p-tau in CSF might be shared not only by CNS involvement of HSV infection but also by CNS VZV infection. This combination of biomarker changes, the so-called “AD signature”, has been considered to indicate the presence of AD pathology. In particular, high levels of p-tau at threonine181 have been reported to occur solely in AD and not in other neurodegenerative disorders or acute brain damage, such as acute brain infarction [6]. The CSF p-tau elevation in the HSV/VZV group might be attributed to the herpetic infection-induced APP mis-metabolism [7], as similarly seen in the case of AD. In addition, the fact that the biomarker profile in AD patients mimics that in patients with CNS HSV and VZV infections suggests that the latter may be a confounding factor in the CSF biomarker-based diagnosis.

Second, the elevations of CSF sTREM2 and GFAP in the HSV and VZV groups are in line with previous...
observations [8]. These trends are also consistent with the reported biomarker changes in patients with AD [9, 10].

Third, only the NfL levels were significantly correlated with the severity and a poor outcome after age adjustment in the CSF biomarkers. This suggests that the NfL concentration in CSF obtained for the diagnostic purpose on admission is the most powerful predictive marker for the severity and prognosis in patients with herpes virus infections among the molecules tested in this study. The CSF and blood NfL levels are reported to be tightly correlated in neurological disorders. Here we found that the serum levels of NfL were strongly associated with their matching CSF levels (Supplementary Fig. S3) and consequently, the ability of serum NfL to evaluate the severity and to predict prognosis may be equivalent to those of CSF NfL.

We acknowledge that the small sample size was a major limitation of this study. Furthermore, the short follow-up period may have weakened the statistical power to detect an association between the prognosis and biomarkers. In the future, it will be necessary to conduct large-scale case-control studies and prospective observations in order to validate the clinical significance of AD-related biomarkers in patients with CNS HSV and VZV infections.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40035-020-00227-w.

Additional file 1: Supplementary methods. Table S1: Characteristics of the participants. Table S2. The concentrations of biomarkers in the HSV, VZV, and control groups (A: CSF Aβ42, B: CSF Aβ40, C: CSF Aβ42/40 ratio, D: CSF t-tau, E: CSF p-tau, F: CSF p-tau/t-tau ratio, G: CSF NfL, H: CSF pNFH, I: CSF sTREM2, J: CSF GFAP, and K: serum NfL). Figure S1. Comparison of biomarker concentrations among the HSV, VZV, and control groups (A: CSF t-tau, B: CSF p-tau, C: CSF p-tau/t-tau ratio, D: CSF NfL, E: CSF NfH). Figure S2. Scatter plots of the biomarkers vs. the lowest score of GCS during hospitalization (A, B, C, D) as well as the biomarkers vs. mRS score at discharge (E, F, G, H, I, J, K) in the HSV/VZV group. Figure S3. Correlations between CSF and serum NfL levels. There was a strong positive correlation between CSF- and serum NfL levels by Spearman’s rank correlation test (p < 0.0001).

Abbreviations

CNS: Central nervous system; AD: Alzheimer’s disease; HSV: Herpes simplex virus; VZV: Varicella zoster virus; Aβ: Amyloid β; t-tau: Total tau; p-tau: Tau phosphorylated at threonine 181; NfL: Neurofilament light chain; p-NFH: Phosphorylated neurofilament heavy chain; GFAP: Glial fibrillary acidic protein; sTREM2: Soluble triggering receptor expressed on myeloid cells 2; CSF: Cerebrospinal fluid

Acknowledgements

Not applicable.

Authors’ contributions

F. K-M, T.O. and Y.F. assisted with patient enrollment, data analysis, and interpretation. H.T., F.K-M., and M.S. performed laboratory work and data analysis. D.A. and T.M. participated in review and revision of the manuscript. M.S., T.K. and T. T were involved in conceptualization and design of the study, patient enrollment, data collection, interpretation of the data, and review of the manuscript. All authors reviewed the drafts and approved the final version of the manuscript.

Funding

This work was mainly supported in part by a grant from the Japan Agency for Medical Research and Development (AMED) (to T.T.), and partially by Grants-in-Aid (Nos. 15 K09319 and 18 K07506 to TK; No. 20 K16605 to T.O.; No. 18 K15461 to HT) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and research grants from Danippon Sumitomo Pharma in 2018 (to T.O.) and 2017 (to TK).

Availability of data and materials

All data generated or analyzed during this study are included in this published article and its supplementary information files.

Ethics approval and consent to participate

Written informed consent from the participants was obtained when possible and, if not, from the nearest relative. The study protocols were approved by the Ethics Committee (ERB-G-12, Kyoto Prefectural University of Medicine, Kyoto, Japan).

Consent for publication

Not applicable.

Competing interests

The authors had no competing financial interests. Also, no non-financial conflicts of interest existed.

Author details

1Department of Neurology, Kyoto Prefectural University of Medicine, Kyoto 602-0841, Japan. 2Department of Functional Brain Imaging Research, National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan. 3Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster LA1 4YQ, UK.

Received: 13 September 2020 Accepted: 1 December 2020

Published online: 04 January 2021

References

1. Itzhaki RF. Corroboration of a major role for herpes simplex virus type 1 in Alzheimer’s disease. Front Aging Neurosci. 2018;10:324.
2. Lovheim H, Galthorpe L, Johansson A, Eriksson S, Hallmans G, Eigh F. Herpes simplex infection and the risk of Alzheimer’s disease: a nested case-control study. Alzheimers Dement. 2015;11:587–92.
3. Chen VC, Wu SI, Huang KY, Yang YH, Kuo TY, Liang HY, et al. Herpes zoster and dementia: a nationwide population-based cohort study. J Clin Psychiatry. 2018;79(1):e11312.
4. Krut JJ, Zetterberg H, Blennow K, Cirque P, Hagberg L, Price RW, et al. Cerebrospinal fluid Alzheimer’s biomarker profiles in CNS infections. J Neurol. 2013;260(2):620–6.
5. Di Stefano A, Alcantarini C, Atzori C, Lipani F, Imperiale D, Bardino E, et al. Cerebrospinal fluid biomarkers in patients with central nervous system infections: a retrospective study. CNS Spectrums. 2020;25(3):402–8.
6. Blennow K, Zetterberg H. Biomarkers for Alzheimer’s disease: current status and prospects for the future. J Intern Med. 2018;284(6):643–63.
7. Civettiri L, Marcocci ME, Celemonti I, Piacentini R, Garaci E, Grassi C, et al. Herpes simplex virus type 1 infection in neurons leads to production and nuclear localization of APP intracellular domain (AICD): implications for Alzheimer’s disease pathogenesis. J Neuro-Oncol. 2015;121(5):480–90.
8. Grahm A, Hagberg L, Nilsson S, Blennow K, Zetterberg H, Studahl M. Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections. J Neurol. 2013;260(7):1813–21.
9. Suárez-Calvet M, Araque Caballero MÁ, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, et al. Early changes in CSF sTREM2 in dominantly inherited Alzheimer’s disease occur after amyloid deposition and neuronal injury. Sci Transl Med. 2016;8(369):369ra178.
10. Oechl P, Hallgebauer S, Andtelt-Straub S, Steinkasser P, Huss AM, Neugebauer H, et al. Glial fibrillary acidic protein in serum is increased in Alzheimer’s disease and correlates with cognitive impairment. J Alzheimers Dis. 2019;67(2):481–